BioCryst Pharmaceuticals BCRX stock news

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is making a run for the top in the premarket hours this morning, and for good reason. Late yesterday, the company said that it would be increasing the number of subjects to be enrolled in a COVID-19 clinical trial. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

BCRX Stock Is Up On Increased Enrollment Expectations

BioCryst Pharmaceuticals is working to bring a new COVID-19 treatment to market. The treatment, known as galidesivir, is an RNA sythesis blocker that the company believes will be effective in the treatment of COVID-19 patients.

Late yesterday, the company announced that it would be greatly expanding the number of patients enrolled. Originally, the two-part clinical study was expected to enroll three dose levels of 8 patients for a total of 24 patients in the first part. The second part would test the best dose in 42 patients, leading to a total patient count of 66 in the study.

Nonetheless, in an announcement made late yesterday, BCRX said that it now intends on enrolling 132 patients into the clinical trial. So, what’s the big deal?

There really isn’t one. However, investors seem to be seeing the larger number of enrolled patients as a sign that galidesivir is working in the early treatment of the first patients. While I wouldn’t say that BCRX isn’t a strong investment, I will say that efficacy is not the reason for the increased enrollment.

The clinical trial was originally posted early this year, where galidesivir would be tested as an option for yellow fever patients. The company shifted the trial to focus on COVID-19 given the current pandemic and need to quickly produce treatments, but didn’t forget about yellow fever.

In fact, the company’s trial description specifically says that it will continue testing the drug as an option for yellow fever independently throughout the study. So, 66 patients on the COVID-19 arm and 66 patients on the yellow fever arm would bring us to 132, and that’s the most likely reason for the increased patient count.

There’s Good Reason To Be Excited Here

Even though the increased patient count is not associated with efficacy, it’s good news. Ultimately, the trial is going to assess the treatment in two key indications. One that is important in the now, and one that is important for the long run.

Ultimately, with two targets on the field, the chances of hitting at 1 of these targets is greatly improved. All in all, there’s good reason for the excitement surrounding BCRX stock today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.